Pasithea Therapeutics Corp. (KTTA)
NASDAQ: KTTA · Real-Time Price · USD
0.5220
+0.0021 (0.40%)
At close: Nov 13, 2026, 4:00 PM EST
0.5200
-0.0020 (-0.38%)
Pre-market: Nov 16, 2026, 4:20 AM EST
Pasithea Therapeutics Employees
Pasithea Therapeutics had 5 employees as of December 31, 2025. The number of employees increased by 1 or 25.00% compared to the previous year. That makes Pasithea Therapeutics the 41,895th largest employer in the world and 6,473rd in the United States.
Employees
5
Change (1Y)
1
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$4,966,719
Market Cap
17.44M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 5 | 1 | 25.00% | 5 | 0 |
| Dec 31, 2024 | 4 | -4 | -50.00% | 4 | 0 |
| Dec 31, 2023 | 8 | -7 | -46.67% | 8 | 0 |
| Dec 31, 2022 | 15 | 10 | 200.00% | 15 | 0 |
| Dec 31, 2021 | 5 | 2 | 66.67% | 3 | 2 |
| Jun 30, 2021 | 3 | - | - | 1 | 2 |
| Mar 31, 2021 | 3 | - | - | 1 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| aTyr Pharma | 60 |
| Atossa Therapeutics | 16 |
| Context Therapeutics | 15 |
| Lipocine | 14 |
| Tvardi Therapeutics | 12 |
| Actuate Therapeutics | 12 |
| Cocrystal Pharma | 10 |
KTTA News
- 2 days ago - Pasithea Therapeutics price target raised to $4 from $3 at H.C. Wainwright - TheFly
- 2 days ago - Pasithea Therapeutics Quarterly report: Q3 2026 - Filings
- 3 days ago - Pasithea Therapeutics presents clinical data from PAS-004-103 study - TheFly
- 3 days ago - Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 European Neurofibromatosis Conference - GlobeNewsWire
- 11 days ago - Pasithea Therapeutics Transcript: KOL event - Transcripts
- 12 days ago - Pasithea gets FDA clearance for Phase 2 PAS-004 trial in skin neurofibromas - TheFly
- 12 days ago - Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF) - GlobeNewsWire
- 18 days ago - Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026 - GlobeNewsWire